Market Closed -
Nasdaq
01:30:00 22/06/2024 am IST
|
5-day change
|
1st Jan Change
|
5.51
USD
|
+5.35%
|
|
-9.38%
|
+35.05%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,833
|
750.2
|
804.3
|
1,220
|
-
|
-
|
Enterprise Value (EV)
1 |
2,691
|
750.2
|
703.2
|
1,231
|
1,031
|
912.1
|
P/E ratio
|
-7.23
x
|
-2.76
x
|
-2.79
x
|
-4.5
x
|
-4.91
x
|
-3.75
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-7.78
x
|
-2.92
x
|
-2.62
x
|
-5.9
x
|
-4.46
x
|
-1.51
x
|
EV / FCF
|
-9.58
x
|
-
|
-2.57
x
|
-5.67
x
|
-5.15
x
|
-4.05
x
|
FCF Yield
|
-10.4%
|
-
|
-38.9%
|
-17.6%
|
-19.4%
|
-24.7%
|
Price to Book
|
4.03
x
|
-
|
2.81
x
|
2.53
x
|
2.67
x
|
-
|
Nbr of stocks (in thousands)
|
1,83,042
|
1,89,920
|
1,97,132
|
2,21,503
|
-
|
-
|
Reference price
2 |
15.48
|
3.950
|
4.080
|
5.510
|
5.510
|
5.510
|
Announcement Date
|
16/03/22
|
16/03/23
|
29/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-280.2
|
-345.8
|
-256.9
|
-268.6
|
-208.6
|
-231.4
|
-605.8
|
EBIT
1 |
-
|
-286.1
|
-356.9
|
-272.6
|
-293.1
|
-278.5
|
-305.5
|
-449.4
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-285.3
|
-355.9
|
-269.5
|
-283.3
|
-271.6
|
-282.9
|
-443.8
|
Net income
1 |
-130.8
|
-285.3
|
-355.9
|
-269.5
|
-283.3
|
-266.2
|
-277.2
|
-430.8
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-6.670
|
-21.92
|
-2.140
|
-1.430
|
-1.460
|
-1.224
|
-1.122
|
-1.468
|
Free Cash Flow
1 |
-
|
-161.9
|
-280.9
|
-
|
-273.6
|
-217
|
-200
|
-225
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/11/20
|
24/03/21
|
16/03/22
|
16/03/23
|
29/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-28.07
|
-69.1
|
-82.17
|
-
|
-79.71
|
-111.8
|
-
|
-79.36
|
-107
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-111.3
|
-31.68
|
-72.9
|
-86.19
|
-81.79
|
-84.05
|
-116.3
|
-2.181
|
-90.62
|
-110.7
|
-67.55
|
-65.24
|
-64.06
|
-77.05
|
-85.69
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-110.7
|
-31.45
|
-72.46
|
-85.12
|
-80.44
|
-82.12
|
-114
|
0.984
|
-88.12
|
-107.5
|
-67.79
|
-68.08
|
-68.38
|
-77.05
|
-85.69
|
Net income
1 |
-110.7
|
-31.45
|
-72.46
|
-85.12
|
-80.44
|
-82.12
|
-114
|
0.984
|
-88.12
|
-107.5
|
-67.79
|
-68.08
|
-68.38
|
-77.05
|
-85.69
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.6000
|
-0.1700
|
-0.3900
|
-0.4500
|
-0.4200
|
-0.4300
|
-0.5900
|
-
|
-0.4500
|
-0.4900
|
-0.2780
|
-0.2680
|
-0.2640
|
-0.3300
|
-0.3700
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
16/03/22
|
10/05/22
|
04/08/22
|
02/11/22
|
16/03/23
|
08/05/23
|
03/08/23
|
08/11/23
|
29/02/24
|
08/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
10.6
|
-
|
-
|
Net Cash position
1 |
-
|
52.9
|
142
|
-
|
101
|
-
|
190
|
308
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-0.0508
x
|
-
|
-
|
Free Cash Flow
1 |
-
|
-162
|
-281
|
-
|
-274
|
-217
|
-200
|
-225
|
ROE (net income / shareholders' equity)
|
-
|
-80.8%
|
-194%
|
-
|
-72%
|
-75.7%
|
-75%
|
-64.3%
|
ROA (Net income/ Total Assets)
|
-
|
-49.8%
|
-32.1%
|
-
|
-40.8%
|
-42%
|
-41.4%
|
-38%
|
Assets
1 |
-
|
572.8
|
1,110
|
-
|
694
|
633.6
|
670
|
1,135
|
Book Value Per Share
2 |
-
|
-
|
3.840
|
-
|
1.450
|
2.180
|
2.060
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
23.9
|
29.9
|
-
|
20
|
18
|
12.5
|
13
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/11/20
|
24/03/21
|
16/03/22
|
16/03/23
|
29/02/24
|
-
|
-
|
-
|
Last Close Price
5.51
USD Average target price
12.2
USD Spread / Average Target +121.42% Consensus |
1st Jan change
|
Capi.
|
---|
| +35.05% | 122.05Cr | | +34.14% | 5.11TCr | | -6.54% | 3.94TCr | | +36.33% | 3.85TCr | | +12.62% | 2.64TCr | | -12.11% | 2.62TCr | | -13.43% | 2.1TCr | | +43.73% | 1.4TCr | | +31.81% | 1.25TCr | | -4.54% | 1.16TCr |
Other Biotechnology & Medical Research
|